Related Experiment Videos
Extracellular matrix dynamics in heart failure: a prospect for gene therapy
1Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson 39216-4505, USA.
Journal of Cellular Biochemistry
|March 11, 1998
Summary
Gene therapy targeting the extracellular matrix (ECM) may improve heart function in heart failure by modulating matrix metalloproteinases (MMPs) and other ECM components.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Biotechnology
Background:
- Chronic heart failure involves impaired myocardial extracellular matrix (ECM) remodeling.
- Activated matrix metalloproteinases (MMPs) in failing hearts contribute to adverse ECM remodeling.
- This remodeling is linked to cardiac structural deformation and heart failure progression.
Purpose of the Study:
- To investigate the potential of ECM gene therapy for treating heart failure.
- To explore modulating ECM components like MMPs, TIMPs, TGF-beta1, decorin, and collagen.
Main Methods:
- Utilizing transgenic technology and in vivo gene transfer techniques.
- Focusing on the overexpression or downregulation of specific ECM genes.
Main Results:
- Studies support the role of impaired ECM remodeling and MMP activation in heart failure.
- No prior programs have specifically aimed to investigate ECM gene therapy in heart failure.
Conclusions:
- ECM gene therapy presents a potential strategy to improve cardiac function in heart failure.
- Modulating ECM components offers a novel therapeutic avenue for cardiomyopathy and heart failure.